DS-3939a
Based on 1 Customer Validation
DS-3939a (DS-3939) is an anti-TA-MUC1 (tumor-associated mucin-1) antibody-drug conjugate (ADC). DS-3939a consists of a humanized anti-TA-MUC1 IgG1 monoclonal antibody Gatipotuzumab ( HY-P99634), a stable and cleavable tetrapeptide-based linker (Gly-Gly-Phe-Gly), and a DNA topoisomerase I inhibitor payload (DXd) (HY-13631D), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). DS-3939a inhibits the growth of TA-MUC1-positive cancer cells (CFPAC-1, NCI-H2110) by inducing DNA damage and apoptosis. DS-3939a exhibits significant antitumor activity in a variety of TA-MUC1-expressing advanced solid tumors. DS-3939a can be used for the study of TA-MUC1-expressing advanced cancers.
For research use only. We do not sell to patients.
- Purity: 99.15%
-
Storage:
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Topoisomerase Isoforms
More
Biological Activity
|
MUC1 |
Topoisomerase I |
DS-3939a (0.01-10000 ng/mL, 6 d) inhibits the growth of TA-MUC1-positive CFPAC-1 and NCI-H2110 cells[1].
DS-3939a (3 μg/mL, 2 d) upregulates the expression of γH2AX and cleaved PARP in TA-MUC1-positive CFPAC-1 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:TA-MUC1-positive CFPAC-1 cells
-
Concentration:3 μg/mL
-
Incubation Time:2 d
-
Result:Upregulated the expression of γH2AX and cleaved PARP in TA-MUC1-positive CFPAC-1 cells.
DS-3939a (10 mg/kg, i.v., once on day 0) exerts potent antitumor activity against TA-MUC1-positive NCI-H2110 lung cancer xenografts but no effect on TA-MUC1-negative HCT-15 colorectal cancer xenografts in female nude mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CFPAC-1 pancreatic cancer cells (1.0×107 cells in 0.1 mL saline) were subcutaneously implanted into the right flanks of 4-5-week-old female nude mice[1]
-
Dosage:0.25, 0.5, 1, 2, 4, 8 mg/kg
-
Administration:i.v., once on day 0
-
Result:Achieved dose-dependent tumor growth inhibition.
-
Animal Model:NCI-H2110 lung cancer cells or HCC70 triple-negative breast cancer cells were subcutaneously implanted into the flanks of 4-5-week-old female nude mice[1]
-
Dosage:10 mg/kg
-
Administration:i.v., once on day 0
-
Result:Exerted potent antitumor activity against TA-MUC1-positive NCI-H2110 lung cancer xenografts but no effect on TA-MUC1-negative HCT-15 colorectal cancer xenografts.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[DS-3939a]
-
Synonyms
DS-3939
-
Shipping
Shipping with dry ice.
-
Storage
-80°C, protect from light
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
DS-3939a Related Classifications
HY-177442 Related Classifications
Powered by Bioz